In conclusion, these findings demonstrate that inhibiting the JAK2/STAT3/HMGCS2 signaling pathway with ruxolitinib and S3I-201 alleviates mitochondrial dysfunction, oxidative stress, and cardiac dysfunction caused by hyperuricemia. Here, HMGCS2 is linked to hyperuricemia.